ASP Isotopes (NASDAQ:ASPI) Hits New 1-Year Low After Insider Selling

Posted by Geri Gentry on Sep 11th, 2026

ASP Isotopes Inc. (NASDAQ:ASPI – Get Free Report) hit a new 52-week low during mid-day trading on Friday after an insider sold shares in the company. The company traded as low as $3.42 and last traded at $3.4280, with a volume of 605382 shares trading hands. The stock had previously closed at $3.59.

Specifically, COO Robert Ainscow sold 8,438 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $4.29, for a total value of $36,199.02. Following the transaction, the chief operating officer owned 2,248,441 shares in the company, valued at approximately $9,645,811.89. This represents a 0.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Wednesday, June 24th. Wall Street Zen raised ASP Isotopes from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $13.00.

Get Our Latest Report on ASPI

ASP Isotopes Price Performance

The company’s fifty day moving average price is $4.21 and its 200 day moving average price is $5.16. The company has a market capitalization of $525.09 million, a P/E ratio of -2.59 and a beta of 3.59. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76.

ASP Isotopes (NASDAQ:ASPI – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The business had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%.

Hedge Funds Weigh In On ASP Isotopes

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in ASP Isotopes during the second quarter worth about $57,331,000. Encompass Capital Advisors LLC bought a new position in ASP Isotopes in the 1st quarter valued at about $30,551,000. Alyeska Investment Group L.P. increased its holdings in ASP Isotopes by 73.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after buying an additional 2,072,851 shares during the period. AWM Investment Company Inc. acquired a new position in shares of ASP Isotopes in the 2nd quarter valued at approximately $9,837,000. Finally, UBS Group AG raised its position in shares of ASP Isotopes by 150.3% in the 4th quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock valued at $12,875,000 after buying an additional 1,445,165 shares in the last quarter. 16.80% of the stock is owned by institutional investors and hedge funds.

ASP Isotopes Company Profile

(Get Free Report)

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.